Delving into the Latest Updates on Ivermectin with Synapse

Overview

Basic Info

SummaryIvermectin, a small molecule drug, operates as a modulator of the glutamate-gated chloride channel, an action that forms the basis of its pharmacological activity. The drug was granted approval by the FDA in November 1996, and its development can be attributed to the remarkable efforts of Merck Sharp & Dohme Corp. Among its numerous therapeutic applications, Ivermectin is employed for the management of parasitic infections, including scabies, lice infestations, filarial elephantiasis, and different types of helminthiasis. Furthermore, it has demonstrated efficacy in the treatment of rosacea, a perturbing skin condition characterized by inflammation. Ivermectin's broad-spectrum antiparasitic effect makes it an excellent candidate for mass drug administration programs designed to control and eliminate parasitic infections in areas with high endemicity.

Drug Type

Small molecule drug

Synonyms

mdc-STM

+ [13]

Target

GluCls

Mechanism

Glutamate-gated chloride channel modulators

Therapeutic Areas

Infectious DiseasesHemic and Lymphatic DiseasesSkin and Musculoskeletal Diseases+ [2]

Active Indication

RosaceaLice InfestationsScabies+ [8]

Inactive Indication

Acne VulgarisDermatitis, AtopicPediculus capitis infestation

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization

MSD KKMerck Canada, Inc.

Arbor Pharmaceuticals LLC

+ [5]

Inactive Organization

Galderma Holding SAGalderma Research & Development SNCTaro Pharmaceuticals U.S.A., Inc.

Drug Highest PhaseApproved

First Approval Date

US (22 Nov 1996),

OnchocerciasisStrongyloidiasis

RegulationOrphan Drug (JP)

Login to view timeline

Structure

Molecular FormulaC47H72O14

InChIKeyVARHUCVRRNANBD-PVVXTEPVSA-N

CAS Registry70209-81-3

This is an open label prospective pharmacokinetic single arm study in Laos PDR. This study will be embedded within a cluster-randomized controlled trial of interventions to address childhood undernutrition (SUANHOAM Trial, ACTRN12620000520932) and involves a collaboration with the Murdoch Children's Research Institute, Burnet institute and Lao Tropical and Public Health Institute.
ITCHY Study:
The primary objective is to determine in young children aged 2 to <5 years and weighing 10 to <15 kg if an ivermectin dose of 3 mg achieves comparable drug exposures to the recommended dose in older children. It aims to provide reliable evidence for a safe and effective dose of ivermectin in young children who are especially vulnerable to scabies infections and the associated secondary complications.
ITCHY2 Study:
An embedded phase 2 multicentre, open label prospective pharmacokinetic study in Laos PDR of ITCHY Study. The primary objective is to determine the plasma ivermectin drug exposure in children aged 3 months to 2 years and weighing ≥2 kg receiving an age specific ivermectin dose.

Start Date01 Oct 2024

Sponsor / Collaborator

Murdoch Childrens Research Institute

[+1]

NCT06404333 / Not yet recruitingPhase 2IIT

A Randomized Trial to Assess the Safety, Pharmacokinetics, Acceptability, and Efficacy of Pediatric Oral Ivermectin in Scabies Infected Children Weighing 5 to Less Than 15 Kilograms

The EPIC-15 trial will evaluate the safety, pharmacokinetics, acceptability, and efficacy of pediatric ivermectin (CHILD-IVITAB) in scabies infected children weighing 5 to less than 15 kg. This trial will support future efforts to expand the indication of ivermectin treatment to infants weighing 5 to less than 15 kg to treat numerous NTDs, allowing this young age group equitable access to the numerous benefits of pediatric ivermectin therapy

Start Date01 Oct 2024

Sponsor / Collaborator

University of Oxford

[+2]

NCT06497075 / Active, not recruitingNot ApplicableIIT

The Feasibility and Acceptability of the Co-administration of Ivermectin and Albendazole Vs Albendazole Alone, in the Frame of Mass Drug Administration to School-aged Children in Uganda: a Small-scale Implementation Pilot Study

The goal of this small-scale implementation research pilot study is to assess the feasibility and acceptability of the co-administration of ivermectin (IVM) and albendazole (ALB) compared to albendazole alone during school-based mass drug administration in Uganda. The study will target up to 10,000 school-aged children from 20 schools in Kabale and Kisoro districts in South-Western Uganda.
The main questions it aims to answer are:
* How feasible is the introduction of co-administered IVM plus ALB in the routine school-based deworming campaign in terms of training, material and processes?
* How well do beneficiary communities (pupils, parents) and implementers (teachers, health workers) accept the new treatment scheme and what are potential barriers and enablers for uptake?
* What are common implementation-related costs that can inform the methodology to estimate monetary and non-monetary costs as well as performance of the two treatment arms for the future cost-effectiveness analysis?
The study employs a cross-sectional mixed-method design (we will collect qualitative and quantitative data) to evaluate the feasibility and acceptability of co-administering IVM and ALB versus ALB alone in routine school-based mass drug administration. Assessments will take place during and after the drug distribution to document the implementation process and evaluate experiences made by the different stakeholders (e.g. children, parents, teachers, health workers):
* The implementation activities start with a training of all implementers at district level who will also undergo a pre- and post-training knowledge assessment.
* Schoolchildren aged 5-14 years will receive a single dose of ALB alone or co-administered ALb (400mg) and IVM (200µg/kg; as determined by height category on a dose pole) by health workers at school. 1-2 weeks post-distribution a subsample of 19 children per school will be invited to answer to questionnaires administered by social science researchers.
* Implementers will administer the treatments and document all distribution-related aspects during the campaign under supervision of the routine staff. Researchers will conduct additional monitoring and evaluation in order to assure data quality and provide support in performance assessment and cost evaluation.
* Beneficiaries (parents) and implementers will be asked to take part in focus group discussions and questionnaire interviews one week after the drug distribution.

Start Date01 Jul 2024

Sponsor / Collaborator

Swiss Tropical & Public Health Institute

[+1]

100 Clinical Results associated with Ivermectin

Login to view more data

100 Translational Medicine associated with Ivermectin

Login to view more data

100 Patents (Medical) associated with Ivermectin

Login to view more data

7,487

Literatures (Medical) associated with Ivermectin

31 Dec 2024·Global Public Health

Pharmaceutical messianism and the politics of COVID-19 in the United States

Article

Author: Lasco, Gideon ; Yu, Vincen Gregory ; Bharti, Nishtha

Throughout the COVID-19 pandemic, public officials in the United States - from the President to governors, mayors, lawmakers, and even school district commissioners - touted unproven treatments for COVID-19 alongside, and sometimes as opposed to, mask and vaccine mandates. Utilising the framework of 'pharmaceutical messianism', our article focuses on three such cures - hydroxychloroquine, ivermectin, and monoclonal antibodies - to explore how pharmaceuticals were mobilised within politicised pandemic discourses. Using the states of Utah, Texas, and Florida as illustrative examples, we make the case for paying attention to pharmaceutical messianism at the subnational and local levels, which can very well determine pandemic responses and outcomes in contexts such as the US where subnational governments have wide autonomy. Moreover, we argue that aside from the affordability of the treatments being studied and the heterodox knowledge claiming their efficacy, the widespread uptake of these cures was also informed by popular medical (including immunological) knowledge, pre-existing attitudes toward 'orthodox' measures like vaccines and masks, and mistrust toward authorities and institutions identified with the 'medical establishment'. Taken together, our case studies affirm the recurrent nature of pharmaceutical messianism in times of health crises - while also refining the concept and exposing its limitations.

02 Dec 2024·Journal of Biomolecular Structure and Dynamics

Repurposing of antiparasitic drugs against the NS2B-NS3 protease of the Zika virus

Article

Author: Jena, N. R. ; Pant, S.

To date, no approved drugs are available to treat the Zika virus (ZIKV) infection. Therefore, it is necessary to urgently identify potential drugs against the ZIKV infection. Here, the repurposing of 30 antiparasitic drugs against the NS2B-NS3 protease of the ZIKV has been carried out by using combined docking and molecular dynamics- (MD) simulations. Based on the docking results, 5 drugs, such as Amodiaquine, Primaquine, Paromomycin, Dichlorophene, and Ivermectin were screened for further analysis by MD simulations and free energy calculations. Among these drugs, Amodiaquine and Dichlorophen are found to produce the most stable complexes and possess relative binding free energies of about -44.3 ± 3.7 kcal/mol and -41.1 ± 5.3 kcal/mol respectively. Therefore, they would act as potent small-molecule inhibitors of the ZIKV protease.However, evaluations of biological and safety activities of these drugs against the ZIKV protease are required before their clinical use.Communicated by Ramaswamy H. Sarma.

01 Dec 2024·Veterinary Parasitology

The efficacy of essential oil components with ivermectin against Rhipicephalus annulatus: An in-vitro study

Article

Author: Kamel, Asmaa A ; Reyad, Abdulrahman ; Arafa, Walid M. ; Aboelhadid, Shawky M. ; Ibrahium, Samar M. ; Kamel, Asmaa A. ; Ibrahium, Samar M ; Abdel-Baki, Abdel-Azeem S. ; Arafa, Walid M ; Gadelhaq, Sahar M. ; Aboelhadid, Shawky M ; Al-Quraishy, Saleh ; Abdel-Baki, Abdel-Azeem S ; Gadelhaq, Sahar M

Ivermectin (Iv) is widely used to control Rhipicephalus annulatus infestations in cattle in Egypt. However, increasing resistance to ivermectin necessitates alternative approaches. This study aimed to address this resistance by investigating the interactions between ivermectin and essential oil components (EOCs)-carvacrol, cinnamaldehyde, D-limonene, trans-anethole, and thymol-against four R. annulatus tick isolates collected from Beni-Suef, El-Minia, and El-Fayoum. The larval immersion test was conducted using various ivermectin concentrations (3, 1.5, 0.75, 0.38, 0.19, 0.09, 0.045, 0.025, and 0.0125 mg/mL) prepared in EthTX1 %. Additionally, EOCs were tested at different concentrations (20, 10, 5, and 2.5 mg/mL) prepared by dilution in 5 % ethyl alcohol and EthTX 1 %. Ivermectin and each EOC were tested individually against the isolates. Subsequently, the LC50 of ivermectin was combined with the LC50 of each EOC in a 1:1 ratio to evaluate potential synergistic effects. All EOCs demonstrated significant toxicity against the isolates. The combination of carvacrol and thymol with ivermectin increased mortality, but the combination index (CI) exceeded one for all isolates, indicating no synergism. Similarly, while D-limonene, cinnamaldehyde, and trans-anethole also resulted in high mortality rates, including up to 100 %, no synergism was observed (CI > 1). However, these three EOCs exhibited CIs close to 1, suggesting an additive effect when combined with ivermectin. In conclusion, combining ivermectin with certain EOCs, particularly D-limonene, cinnamaldehyde, and trans-anethole, may offer an effective tool for controlling cattle ticks. Developing topical or pour-on formulations of ivermectin-EOC combinations could be an integral part of integrated management strategies to combat resistance to macrocyclic lactones like ivermectin. Further studies, including tests on adult ticks and field trials, are needed to evaluate the efficacy of these combinations.

75

News (Medical) associated with Ivermectin

14 Nov 2024

·endpts.com

Trump picks vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy

President-elect Donald Trump has picked Robert F. Kennedy Jr. to be his next HHS secretary, likely giving the government’s most powerful healthcare post to a vaccine skeptic whose controversial views would be a huge break with decades of US health and scientific policies. “For too long, Americans have been crushed by the industrial food complex and drug companies who have engaged in deception, misinformation and disinformation when it comes to public health,” Trump said in a social media post announcing the selection. Kennedy is a longtime anti-vaccine crusader and environmental advocate who dropped out of the presidential race to endorse Trump in August. His “Make America Healthy Again” platform — a riff on Trump’s campaign slogan — emerged as a priority from various members of the former president’s camp, including Trump himself. HHS is a massive agency that oversees nearly $2 trillion in federal spending. Its sub-agencies include the governance of Medicare and Medicaid, drug and food regulation at the FDA, the sprawling scientific work of the NIH, and numerous other bodies overseeing everything from public health to biodefense. Last month, Kennedy gave a preview of what his leadership of the agency would mean. In a post on X, he said that “FDA’s war on public health is about to end,” and calling for stopping what he called the suppression of “psychedelics, peptides, stem cells, raw milk, hyperbaric therapies, chelating compounds, ivermectin, hydroxychloroquine, vitamins, clean foods, sunshine, exercise, nutraceuticals and anything else that advances human health and can’t be patented by Pharma.” Biotech stocks fell on reports of the pick, with the Nasdaq Biotech Index declining 2.4% at the close. Shares of vaccine makers fell as well, with Moderna $MRNA dropping 5.6% after the news broke and Pfizer $PFE down 2.6%. Trump has promised to give Kennedy wide latitude on healthcare issues. “I’m gonna let him go wild on health,” Trump said at an October campaign event in Madison Square Garden in New York. “I’m gonna let him go wild on the food. I’m gonna let him go wild on the medicines.” A name mentioned as a possible FDA pick under a Kennedy HHS is Casey Means, a Stanford-trained physician-turned-wellness advocate who might prove to be almost as controversial as Kennedy. Means, like Kennedy, has raised questions about the safety of vaccines, implying a link to autism. Such a link has never been proven, and an older study that has been the basis of many of those claims has been retracted and debunked. In addition to Kennedy’s anti-vaccine views, he has threatened to eliminate portions of federal health agencies and push out or discipline staff. “If you work for the FDA and are part of this corrupt system, I have two messages for you: 1. Preserve your records, and 2. Pack your bags,” Kennedy said in the October post on X . He has also espoused a number of more mainstream positions, including calling for a focus on wellness and the prevention of chronic disease, overhauling regulations for direct-to-consumer pharmaceutical ads, having Americans pay no more than other developed nations for drugs, and eliminating many pollutants and additives from the food supply, according to an opinion piece he wrote for the Wall Street Journal in September . But many of those views have been overshadowed by Kennedy’s embrace of conspiracy theories, such as his apparent support for the idea that high-altitude airplane contrails are in fact a government program to disperse chemicals. (They are actually condensed water.) Those positions could make for a less-than-certain Senate confirmation process, since they would almost certainly include a thorough review of his many controversial positions that are at odds with much of the healthcare establishment, as well as a number of recent personal scandals . Kennedy would hardly be the only controversial choice for the Trump administration. This week, he said he had chosen former Rep. Matt Gaetz of Florida to be his attorney general . Gaetz has been the subject of an ethics complaint over allegations of sex trafficking, as well as a fierce Trump ally and critic of the Department of Justice. Editor’s note: This story has been updated throughout with new details.

VaccineExecutive Change

14 Nov 2024

·www.adalvo.com

Adalvo announces successful DCP Submission for Ivermectin topical cream

Adalvo is pleased to announce the successful EU DCP Submission for Ivermectin 10mg/g topical cream. Our Ivermectin cream is being developed in collaboration with one of our strategic partners, based on the reference brand Soolantra, Galderma. The product is used on the skin to treat pimples and spots found with rosacea. According to IQVIA, the INN with strength 1%(10mg/g) generated approximately $214mn in global sales in 2022. With our clearly defined product pathway, we believe Adalvo will be amongst the first wave of filers, and will be ready to launch on Day-1 in all major markets. As a company committed to our dermatology portfolio, we offer an array of dossiers and aim to assist our partners in overcoming any challenges that may arise with these mature products. Our dermatology products include: Adapalene Gel Adapalene + Benzoyl Peroxide Gel Tacrolimus Ointment Dimetindene Gel

12 Nov 2024

·www.globenewswire.com

Timor-Leste eliminates lymphatic filariasis as a public health problem

DECATUR, Ga., Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Mectizan Donation Program applauds Timor-Leste for eliminating lymphatic filariasis (LF) as a public health problem, a remarkable achievement that was recently validated by the World Health Organization (WHO). Timor-Leste is the fifth country in Southeast Asia to achieve this milestone and the first country in the region to do so by co-administering Mectizan, albendazole and diethylcarbamazine (DEC). Since 2017, Merck (known as MSD outside of the U.S. and Canada), GSK and Eisai have been partnering to donate Mectizan, albendazole, and DEC, respectively, to accelerate the elimination of LF in eligible countries where river blindness is not endemic based on a recommendation of triple drug therapy from WHO. LF, commonly known as elephantiasis, is a debilitating disease caused by a parasite transmitted by mosquitoes. Long-term, chronic infection can cause damage to the lymphatic system, as well as severe and irreversible swelling to the limbs, breasts and/or genitals. These symptoms can cause extreme discomfort, disability and social stigmatization. “We are delighted to learn of Timor-Leste’s success in eliminating LF as a public health problem,” said Allison Goldberg, president, Merck Foundation. “This achievement is a testament to the strength and determination of the Timor-Leste people and the power of public-private partnerships, including the Mectizan Donation Program.”Thomas Breuer, Chief Global Health Officer at GSK, stated, “We congratulate Timor-Leste for this remarkable achievement. The elimination of lymphatic filariasis as a public health problem in Timor-Leste is demonstrative of the power of effective partnerships and the unwavering commitment of the global NTD community.” Mectizan Donation Program director Dr. Yao Sodahlon, an expert in tropical diseases who played a vital role in the elimination of LF in Togo, stated, “We celebrate the government of Timor-Leste, the endemic communities who helped distribute the medicines with high coverage demonstrating effectiveness of triple drug therapy, and the partners who made elimination of LF in Timor-Leste possible. This success demonstrates that elimination of LF can be achieved through the donations of these essential medicines, the commitment of the government and people of the endemic countries, and the global partnership working to end LF.” About the Mectizan Donation Program The Mectizan Donation Program (MDP) was established in 1987 to provide medical, technical, and administrative oversight of the donation of Mectizan by Merck for the treatment of onchocerciasis, also known as river blindness. In 1998, MDP expanded its mandate to include oversight of the donation of albendazole by GSK for the elimination of lymphatic filariasis in onchocerciasis co-endemic areas. Contacts MDP:Joni Lawrence Deputy Director Mectizan Donation Program jlawrence@taskforce.org Yao SodahlonDirectorMectizan Donation Programysodahlon@taskforce.org

100 Deals associated with Ivermectin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00804	Ivermectin	D11AX22 P02CF01	DB00602

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Rosacea	US	Galderma Laboratories LP	19 Dec 2014
Lice Infestations	US	Arbor Pharmaceuticals LLC	07 Feb 2012
Scabies	JP	MSD KK	21 Aug 2006
Ascariasis	CN	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Elephantiasis, Filarial	CN	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Enterobiasis	CN	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Hookworm Infections	CN	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Trichuriasis	CN	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 2001
Onchocerciasis	US	Merck Sharp & Dohme Corp.	22 Nov 1996
Strongyloidiasis	US	Merck Sharp & Dohme Corp.	22 Nov 1996

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acne Vulgaris	Preclinical	CA	Galderma Holding SA	25 Apr 2016
Acne Vulgaris	Preclinical	FR	Galderma Holding SA	25 Apr 2016
Acne Vulgaris	Preclinical	CA	Galderma Research & Development SNC	25 Apr 2016
Dermatitis, Atopic	Discovery	CA	Galderma Research & Development SNC	01 Nov 2016
Dermatitis, Atopic	Discovery	CA	Galderma Holding SA	01 Nov 2016
Acne Vulgaris	Discovery	DE	Galderma Research & Development SNC	25 Apr 2016
Acne Vulgaris	Discovery	FR	Galderma Research & Development SNC	25 Apr 2016
Acne Vulgaris	Discovery	DE	Galderma Holding SA	25 Apr 2016
Rosacea	Discovery	US	Galderma Holding SA	01 Dec 2011
Rosacea	Discovery	CA	Galderma Holding SA	01 Dec 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03527732 (CTgov)	Phase 2/3	Trichuriasis	1,673	Albendazole (Albendazole in Côte d'Ivoire)	lyzgtfvfvj(ivcroxztwb) = ljkydkcohf blvadaocrg (sqmeirwpbk, bumfgkzzvv - qenyisyyyf) View more	-	20 Mar 2024
				Albendazole+Ivermectin (Albendazole and Ivermectin in Côte d'Ivoire)	lyzgtfvfvj(ivcroxztwb) = avalufhnxr blvadaocrg (sqmeirwpbk, yracqlgmkk - ladseajfwn) View more
NCT04848688 (StrongMoxi_KH, CTgov)	Phase 3	Strongyloidiasis	332	Placebo+Moxidectin 2 mg (Moxidectin)	hlsflzxtvb(vdsdrjompa) = ibzcwbpowh xugjzppems (gwisdtssgs, ijmjcjylyr - eusmetwnro) View more	-	24 Jan 2024
				Placebo+Ivermectin 3 mg (Ivermectin)	hlsflzxtvb(vdsdrjompa) = ukjoscxllw xugjzppems (gwisdtssgs, mofzqnkfck - seyhqhptjw) View more
NCT03967054 (RIMDAMAL II, CTgov)	Phase 3	Malaria	4,124	Ivermectin (Ivermectin Mass Drug Administration)	etligmqwkr(yfbvvkcmlr) = fpmuorzroi jusicypuer (gferjclbwh, uzzupyeucx - lthfsdpjmr) View more	-	11 Jan 2024
				Placebo oral tablet (Placebo Mass Administration)	etligmqwkr(yfbvvkcmlr) = yiryerameu jusicypuer (gferjclbwh, warphazeyq - xpybbmknng) View more
NCT05894538 (CTgov)	Phase 3	COVID-19	1,459	Ivermectin (Arm D - Ivermectin 600)	bisoxyfyxn(wseybgjjwe) = rpbhnlrrwu blgiesefvl (fskxmjlyqo, qylxtyumbv - qhtkljbvkj) View more	-	28 Sep 2023
				Placebo (Arm D - Placebo)	bisoxyfyxn(wseybgjjwe) = nbahmaowwm blgiesefvl (fskxmjlyqo, icdauvnbtz - dytxyiukei) View more
NCT04410406 (Pubmed \| PLoS Negl Trop Dis)	Phase 3	Elephantiasis, Filarial Wuchereria bancrofti microfilaremia	-	ivermectin + albendazole	(sqorpqziwe) = Four participants had transient Grade 3 hematuria after treatment (3 after IDA and 1 after IA) gqhjezjlem (cnddlqpqnn ) View more	Positive	18 Sep 2023
				moxidectin + albendazole
NCT04510194 (COVID-OUT, CTgov)	Phase 3	COVID-19	1,323	Metformin (Treatment Arm - Metformin Only Group)	xvmmphtmrv(hsilziacwv) = epyxtourdy gcyvrjlttq (ijkmkezzyx, myqkgwoeny - itoplukajb) View more	-	13 Jul 2023
				Placebo (Treatment Arm - Placebo Group)	xvmmphtmrv(hsilziacwv) = aqfwszuagc gcyvrjlttq (ijkmkezzyx, dwgmvbpfye - cwrnojwwjy) View more
WCD2023	Not Applicable	Scabies	-	ivermectin (Community residents)	dfzpgciqpe(czhkwsshcf) = vugpylgiuy rojygnswce (yolzdmhikb )	-	06 Jul 2023
WCD2023	Not Applicable	Rosacea	-	Ivermectin 1% cream and doxycycline 40 mg	(kcmdaqwsiz) = pfumzoetuk igyxonujxt (kskyzaquml )	-	03 Jul 2023
				Ivermectin 1% cream and Placebo	(kcmdaqwsiz) = wzkmhcdsxk igyxonujxt (kskyzaquml )
NCT04188301 (DOLF IDA/Oncho, CTgov)	Phase 2	Onchocerciasis	154	Albendazole+Ivermectin (IVM + ALB)	pcvdiicxeo(ddyogmpoyp) = qfqyqucdcd xdteikwvdh (nwiphyvdyh, vfrzechraz - svfkwsgnzj) View more	-	10 May 2023
				albendazole+ivermectin+diethylcarbamazine (IDA x 1 Dose)	pcvdiicxeo(ddyogmpoyp) = fwvjnxacea xdteikwvdh (nwiphyvdyh, bponlshxdq - gooksytfjd) View more
NCT03570814 (Pubmed)	Phase 4	Elephantiasis, Filarial \| Trachoma	13,511	Combined treatment arm (ivermectin, albendazole, azithromycin)	(wlxkmpeuud) = ztzmxmwdfg wfcclerdqr (fognabzjds )	-	01 May 2023
				Control arm (ivermectin, albendazole, azithromycin separately)	(wlxkmpeuud) = snimfhgcyf wfcclerdqr (fognabzjds )